LB Pharmaceuticals Inc Common Stock (LBRX) Stock Ticker
LBRX right now
Market factors today
Unlock the full LBRX picture
About LB Pharmaceuticals Inc Common Stock
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
LBRX stock facts
| Ticker symbol | LBRX |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $1.1B |
| CEO | Heather D. Turner |
| Employees | 49 |
| Headquarters | New York, NY, US |
| IPO date | 2025-09-11 |
| Website | lbpharma.us |
What you can see for LBRX on Tickr
Live LBRX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the LBRX report.
Rankings
FAQ
What is the ticker symbol for LB Pharmaceuticals Inc Common Stock?
The ticker symbol for LB Pharmaceuticals Inc Common Stock is LBRX, listed on the NASDAQ Global Select.
What is LBRX?
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.